- 现金
- 59 元
- 精华
- 0
- 帖子
- 39
- 注册时间
- 2014-11-11
- 最后登录
- 2019-12-20
|
箭头公司疑似操纵股价被投资者起诉,被怀疑对乙肝人体测试数据做不准确描述
The Complaint alleges that defendants misrepresented the true viral reduction level that ARC-520 can induce in humans, and failed to disclose that data from the Phase IIa study of ARC-520 did not support their assertions concerning the drug’s ability to induce a certain reduction level of hepatitis B surface antigens in humans.
On October 8, 2014, the Company announced the results of its Phase IIa study of ARC-520, which revealed that ARC-520 dosed at 2 mg/kg induced a reduction in hepatitis B surface antigens that was far short of the levels defendants previously suggested. Following this news, the Company’s stock dropped $5.48 per share, or almost 44% below its previous closing price, to close at $7.03 per share on October 8, 2014, on extraordinary volume.
http://finance.yahoo.com/news/investor-alert-glancy-binkow-goldberg-173200478.html |
|